Monoclonal antibodies play a vital role in anti-HER2 therapy, with trastuzumab deruxtecan (T-DXd, DS-8201) standing out as a notable example that has shown encouraging antitumor effects in HER2-mutant lung cancer patients. The gene discussed is ERBB2; the disease is lung carcinoma.